OverviewSuggest Edit

Bluebird Bio is a clinical-stage biotechnology company that develops transformative gene therapies for severe genetic diseases and cancer. The Company's clinical programs in severe genetic diseases include LentiGlobin product candidate to treat transfusion dependent β-thalassemia and to treat severe sickle cell disease and itsLenti-D product candidate to treat cerebral adrenoleukodystrophy.

TypePublic
Founded1992
HQCambridge, US
Websitebluebirdbio.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Sep 2019)1,012(+9%)
Job Openings135
Revenue (FY, 2018)$54.6 M(+55%)
Share Price (Nov 2019)$75 (+2%)

Key People/Management at Bluebird Bio

Derek Adams

Derek Adams

Chief Technology and Manufacturing Officer
Jason F. Cole

Jason F. Cole

Chief Operating & Legal Officer
Chip Baird

Chip Baird

CFO
David Davidson

David Davidson

Chief Medical Officer
Stephanie Fagan

Stephanie Fagan

Senior Vice President, Corporate Communications
Alison Finger

Alison Finger

Chief Commercial Officer
Show more

Bluebird Bio Office Locations

Bluebird Bio has offices in Cambridge, Seattle and Zug
Cambridge, US (HQ)
150 Second St
Seattle, US
1616 Eastlake Ave E #208
Zug, CH
135 Baarerstrasse
Show all (3)

Bluebird Bio Financials and Metrics

Bluebird Bio Revenue

Bluebird Bio's revenue was reported to be $54.58 m in FY, 2018
USD

Revenue (Q3, 2019)

8.9m

Gross profit (Q3, 2019)

8.0m

Gross profit margin (Q3, 2019), %

90.3%

Net income (Q3, 2019)

(206.0m)

EBIT (Q3, 2019)

(210.4m)

Market capitalization (15-Nov-2019)

4.1b

Closing stock price (15-Nov-2019)

75.0

Cash (30-Sep-2019)

300.4m

EV

4.0b
Bluebird Bio's current market capitalization is $4.1 b.
Annual
USDFY, 2013FY, 2014Y, 2014FY, 2015Y, 2015FY, 2016FY, 2017FY, 2018

Revenue

20.2m25.4m25.4m14.1m14.1m6.2m35.4m54.6m

Revenue growth, %

26%(45%)(56%)

Cost of goods sold

885.0k

Gross profit

53.7m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

6.3m6.4m6.3m6.3m6.4m6.3m4.9m1.3m1.5m1.6m1.6m6.8m16.7m7.7m16.0m7.9m11.5m12.5m13.3m8.9m

Cost of goods sold

21.0k29.0k430.0k613.0k862.0k

Gross profit

7.8m11.5m12.0m12.7m8.0m

Gross profit Margin, %

100%100%97%95%90%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

206.3m347.8m164.3m278.9m758.5m402.6m

Accounts Receivable

Prepaid Expenses

5.0m4.5m6.0m21.2m19.8m

Inventories

19.8m
USDY, 2019

EV/EBIT

-19.1 x

EV/CFO

-9.9 x

Revenue/Employee

8.8k

Financial Leverage

1.3 x
Show all financial metrics

Bluebird Bio Online and Social Media Presence

Embed Graph

Bluebird Bio News and Updates

What Bluebird Bio Gets Wrong In Pricing For Its $1.8 Million Drug

By enacting the above suggestions, Bluebird Bio can show that it is confident in its product, that it will only get paid if the product works, that it will adjust costs if there is a need for future treatments and that it won’t be opportunistic in taking annual price hikes.

Brainstorm Health: GSK Tesaro Deal, VR Medical Education, Bluebird Bio

Brainstorm Health Daily: December 1, 2018

Gene Therapy Market to Set Phenomenal Growth from 2018 to 2026 Estimated by Global Top Players GlaxoSmithKline plc, Bluebird Bio, Inc., Adaptimmune Therapeutics plc, Celgene Corporation, Shanghai Sunway Biotech Co. Ltd., Merck KGaA, Transgene SA

#Summary: Summary This report includes market status and forecast of global and major regions, with the introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Posted via Industry Today. Follow us on Twi…

Bluebird Bio stock lifts on Regeneron collaboration, $100 mln investment

Bluebird Bio Inc. and Regeneron Pharmaceuticals Inc. plan a five-year collaboration to develop new cell therapies for cancer, the companies announced early Monday. Regeneron will also invest $100 million in Bluebird Bio shares that values them at $238.10 per share, according to the announcement. B…
Show more

Bluebird Bio Frequently Asked Questions

  • When was Bluebird Bio founded?

    Bluebird Bio was founded in 1992.

  • Who are Bluebird Bio key executives?

    Bluebird Bio's key executives are Derek Adams, Jason F. Cole and Chip Baird.

  • How many employees does Bluebird Bio have?

    Bluebird Bio has 1,012 employees.

  • What is Bluebird Bio revenue?

    Latest Bluebird Bio annual revenue is $54.6 m.

  • What is Bluebird Bio revenue per employee?

    Latest Bluebird Bio revenue per employee is $53.9 k.

  • Who are Bluebird Bio competitors?

    Competitors of Bluebird Bio include Modis Therapeutics, Aeglea Biotherapeutics and Immune Design.

  • Where is Bluebird Bio headquarters?

    Bluebird Bio headquarters is located at 150 Second St, Cambridge.

  • Where are Bluebird Bio offices?

    Bluebird Bio has offices in Cambridge, Seattle and Zug.

  • How many offices does Bluebird Bio have?

    Bluebird Bio has 3 offices.